ID   TMD8
AC   CVCL_A442
SY   TMD-8; Tokyo Medical and Dental university 8
DR   EFO; EFO_0006496
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-4956
DR   BioGRID_ORCS_Cell_line; 748
DR   cancercelllines; CVCL_A442
DR   ChEMBL-Cells; CHEMBL4295480
DR   ChEMBL-Targets; CHEMBL4296503
DR   Cosmic; 1486587
DR   Cosmic; 1945194
DR   Cosmic; 2129635
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   GEO; GSM1059801
DR   GEO; GSM1374963
DR   GEO; GSM1527304
DR   GEO; GSM1527305
DR   GEO; GSM1527306
DR   GEO; GSM1527307
DR   GEO; GSM1527308
DR   GEO; GSM1527309
DR   GEO; GSM1890021
DR   GEO; GSM1890022
DR   GEO; GSM1890023
DR   GEO; GSM1890024
DR   GEO; GSM2037048
DR   GEO; GSM2037049
DR   PharmacoDB; TMD8_1600_2019
DR   Progenetix; CVCL_A442
DR   PubChem_Cell_line; CVCL_A442
DR   Wikidata; Q54972694
RX   PubMed=16780947;
RX   PubMed=20054396;
RX   PubMed=21179087;
RX   PubMed=23257783;
RX   PubMed=23292937;
RX   PubMed=25485619;
RX   PubMed=26589293;
RX   PubMed=26787899;
RX   PubMed=27566572;
RX   PubMed=29416618;
RX   PubMed=29666304;
CC   Population: Japanese.
CC   Characteristics: Genetically heterogeneous, consists of 3 subclones (PubMed=27566572).
CC   Doubling time: ~30 hours (PubMed=16780947).
CC   HLA typing: A*02:07,02:07; B*15:01,46:01; C*01:02,01:02 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 1699; CD79B; Simple; p.Tyr196His (c.586T>C); Zygosity=Heterozygous (PubMed=20054396).
CC   Sequence variation: Mutation; HGNC; 7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Heterozygous (PubMed=21179087).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Misspelling: TDM8; PubMed=23292937.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C36081; Diffuse large B-cell lymphoma activated B-cell type
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 30-01-24; Version: 30
//
RX   PubMed=16780947; DOI=10.1016/j.leukres.2006.05.003;
RA   Tohda S., Sato T., Kogoshi H., Fu L., Sakano S., Nara N.;
RT   "Establishment of a novel B-cell lymphoma cell line with suppressed
RT   growth by gamma-secretase inhibitors.";
RL   Leuk. Res. 30:1385-1390(2006).
//
RX   PubMed=20054396; DOI=10.1038/nature08638;
RA   Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B.,
RA   Kohlhammer H., Lamy L., Zhao H., Yang Y.-D., Xu W.-H., Shaffer A.L. III,
RA   Wright G., Xiao W.-M., Powell J.I., Jiang J.-K., Thomas C.J., Rosenwald A.,
RA   Ott G., Muller-Hermelink H.-K., Gascoyne R.D., Connors J.M.,
RA   Johnson N.A., Rimsza L.M., Campo E., Jaffe E.S., Wilson W.H.,
RA   Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R.,
RA   Cook J.R., Weisenburger D.D., Chan W.C., Pierce S.K., Staudt L.M.;
RT   "Chronic active B-cell-receptor signalling in diffuse large B-cell
RT   lymphoma.";
RL   Nature 463:88-92(2010).
//
RX   PubMed=21179087; DOI=10.1038/nature09671;
RA   Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W.-M., Lim K.-H.,
RA   Kohlhammer H., Xu W.-H., Yang Y.-D., Zhao H., Shaffer A.L. III, Romesser P.,
RA   Wright G., Powell J.I., Rosenwald A., Muller-Hermelink H.-K., Ott G.,
RA   Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S.,
RA   Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R.,
RA   Cook J.R., Weisenburger D.D., Chan W.C., Staudt L.M.;
RT   "Oncogenically active MYD88 mutations in human lymphoma.";
RL   Nature 470:115-119(2011).
//
RX   PubMed=23257783; DOI=10.1038/leu.2012.367;
RA   Wenzel S.-S., Grau M., Mavis C., Hailfinger S., Wolf A., Madle H.,
RA   Deeb G., Dorken B., Thome M., Lenz P., Dirnhofer S.,
RA   Hernandez-Ilizaliturri F.J., Tzankov A., Lenz G.;
RT   "MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.";
RL   Leukemia 27:1381-1390(2013).
//
RX   PubMed=23292937; DOI=10.1073/pnas.1205299110;
RA   Zhang J., Grubor V., Love C.L., Banerjee A., Richards K.L.,
RA   Mieczkowski P.A., Dunphy C., Choi W., Au W.Y., Srivastava G.,
RA   Lugar P.L., Rizzieri D.A., Lagoo A.S., Bernal-Mizrachi L., Mann K.P.,
RA   Flowers C.R., Naresh K., Evens A.M., Gordon L.I., Czader M.B., Gill J.I.,
RA   Hsi E.D., Liu Q.-Q., Fan A., Walsh K., Jima D., Smith L.L., Johnson A.J.,
RA   Byrd J.C., Luftig M.A., Ni T., Zhu J., Chadburn A., Levy S.,
RA   Dunson D.B., Dave S.S.;
RT   "Genetic heterogeneity of diffuse large B-cell lymphoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=26787899; DOI=10.1073/pnas.1524677113;
RA   Dekker J.D., Park D., Shaffer A.L. III, Kohlhammer H., Deng W.,
RA   Lee B.-K., Ippolito G.C., Georgiou G., Iyer V.R., Staudt L.M.,
RA   Tucker H.O.;
RT   "Subtype-specific addiction of the activated B-cell subset of diffuse
RT   large B-cell lymphoma to FOXP1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 113:E577-E586(2016).
//
RX   PubMed=27566572; DOI=10.18632/oncotarget.11524;
RA   Quentmeier H., Pommerenke C., Ammerpohl O., Geffers R., Hauer V.,
RA   MacLeod R.A.F., Nagel S., Romani J., Rosati E., Rosen A., Uphoff C.C.,
RA   Zaborski M., Drexler H.G.;
RT   "Subclones in B-lymphoma cell lines: isogenic models for the study of
RT   gene regulation.";
RL   Oncotarget 7:63456-63465(2016).
//
RX   PubMed=29416618; DOI=10.18632/oncotarget.20378;
RA   Liu W., Chen J., Tamayo A.T., Ruan C.-G., Li L., Zhou S.-H., Shen C.,
RA   Young K.H., Westin J., Davis R.E., Hu S.-M., Medeiros L.J., Ford R.J. Jr.,
RA   Pham L.V.;
RT   "Preclinical efficacy and biological effects of the oral proteasome
RT   inhibitor ixazomib in diffuse large B-cell lymphoma.";
RL   Oncotarget 9:346-360(2018).
//
RX   PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004;
RA   Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H.,
RA   Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H.,
RA   Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.;
RT   "Strategic therapeutic targeting to overcome venetoclax resistance in
RT   aggressive B-cell lymphomas.";
RL   Clin. Cancer Res. 24:3967-3980(2018).
//